Fosdenopterin approved to treat adult patients with molybdenum cofactor deficiency (MoCD) Type A

Twitter

Linkedin

Facebook

email

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A

Follow this news feed: